Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $26.25 Average PT from Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $26.25.

TARA has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Oppenheimer upped their price target on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Friday, July 17th.

Protara Therapeutics Stock Up 1.0%

Shares of NASDAQ:TARA opened at $3.94 on Friday. Protara Therapeutics has a 12-month low of $3.02 and a 12-month high of $7.82. The firm has a fifty day moving average of $4.02 and a two-hundred day moving average of $4.75. The firm has a market capitalization of $232.85 million, a P/E ratio of -2.92 and a beta of 1.49.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). Equities research analysts expect that Protara Therapeutics will post -1.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC bought a new stake in Protara Therapeutics during the first quarter valued at about $8,454,000. ADAR1 Capital Management LLC increased its stake in shares of Protara Therapeutics by 3,127.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock worth $6,059,000 after purchasing an additional 1,101,576 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Protara Therapeutics in the fourth quarter worth about $5,562,000. Janus Henderson Group PLC lifted its position in shares of Protara Therapeutics by 21.5% during the 4th quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock worth $27,379,000 after purchasing an additional 910,285 shares during the last quarter. Finally, Integral Health Asset Management LLC boosted its stake in Protara Therapeutics by 60.7% during the 4th quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock valued at $11,992,000 after purchasing an additional 850,000 shares during the period. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.